Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.

@article{Griebel2002AnxiolyticAA,
  title={Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.},
  author={Guy Griebel and Jacques Simiand and Claudine Serradeil-Le Gal and Jean Wagnon and Marc Pascal and Bernard Scatton and J Maffrand and Philippe Soubri{\'e}},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2002},
  volume={99 9},
  pages={6370-5}
}
The limbic localization of the arginine vasopressin V(1b) receptor has prompted speculation as to a potential role of this receptor in the control of emotional processes. To investigate this possibility, we have studied the behavioral effects of SSR149415, the first selective and orally active non-peptide antagonist of vasopressin V(1b) receptors, in a variety of classical (punished drinking, elevated plus-maze, and light/dark tests) and atypical (fear/anxiety defense test battery and social… CONTINUE READING